Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 3

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

NCT00708435 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate correction of INR (International Normalized Ratio)and to stop an acute major bleeding.

Interventions

  • BIOLOGICAL Fresh frozen plasma
  • BIOLOGICAL Beriplex® P/N (Kcentra)

Study Locations (20)

California

  • Study Site — Los Angeles
  • Study Site — San Franciso

Florida

  • Study Site — Orlando
  • Study Site — Tampa

Illinois

  • Study Site — Chicago
  • Study Site — Oak Park

Maryland

  • Study Site — Baltimore
  • Study Site — Baltimore

Massachusetts

  • Study Site — Boston
  • Study Site — Worchester

Michigan

  • Study Site — Ann Arbor
  • Study Site — Royal Oak

Minnesota

  • Study Site — Duluth
  • Study Site — Minneapolis

Alabama

  • Study Site — Birmingham

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2008-06
Est. Completion 2010-11
Phase Phase 3

Sponsor

CSL Behring

85 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00708435

The ClinicalTrials.gov registry entry for NCT00708435 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 85 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Blood Coagulation Disorders appearing as the primary indexed condition, and to 2 interventions — of which Fresh frozen plasma is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00708435 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00708435 about?

NCT00708435 is a clinical study titled "Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy". The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate correction of INR (International Normalized Ratio)and to stop an acute...

What is the current status of trial NCT00708435?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2008-06. Estimated completion is 2010-11.

What conditions does trial NCT00708435 study?

This clinical trial studies the following conditions: Blood Coagulation Disorders, Acute Major Bleeding. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00708435?

The interventions under investigation include: Fresh frozen plasma (BIOLOGICAL), Beriplex® P/N (Kcentra) (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00708435?

This trial is sponsored by CSL Behring, which has 85 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00708435 being conducted?

This trial has 20 study locations across Alabama, California, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial